Assessment of hepatic fibrosis, portal hemodynamic changes, and disease severity in patients with HCV-related liver cirrhosis after sustained virologic response to direct-acting antiviral drugs (DAAs)

Egyptian Liver Journal

Table 7 Correlation between noninvasive biomarkers of liver fibrosis with Doppler findings in the study group 12 months after the end of treatment

		FIB4	APRI score	SWE
Portal vein flow velocity “cm/sec”	r	0.425	0.384	0.320
Portal vein flow velocity “cm/sec”	p	0.03*	0.03*	0.04*
Portal vein diameter “mm”	r	0.511	0.481	0.641
Portal vein diameter “mm”	p	0.02*	0.03*	0.03*
TAMV “cm/s”	r	0.734	0.397	0.364
TAMV “cm/s”	p	0.03*	0.04*	0.04*
Cross-section area “cm²”	r	0.153	0.228	0.664
Cross-section area “cm²”	p	0.02*	0.04*	.03*
Hepatic arterial resistive index	r	0.162	0.216	0.046
Hepatic arterial resistive index	p	0.346	0.672	0.273